Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

4 months ago

A total of 19 patients with serious/life-threatening invasive fungal infections have been enrolled, including aspergillosis, mucormycosis, fusarium, candidiasis, cryptococcosis, and…

Saxony-Anhalt Embraces Change as an Opportunity: Billions Invested in Key Transformation Industries

4 months ago

Companies are currently injecting nearly three billion euros into projects in Saxony-Anhalt, marking a significant commitment to transformative initiatives. When…

MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial

4 months ago

MindBio demonstrates safe, effective take home use of MB22001 in Depressed patients over an 8-week, world first take-home trialRapid, robust,…

Mednition Appoints Deena Brecher as Chief Nursing Officer, Pioneering Commitment to Nurse-First Artificial Intelligence

4 months ago

BURLINGAME, Calif.--(BUSINESS WIRE)--#AI--Mednition, a Silicon Valley leader in clinical artificial intelligence (AI) healthcare solutions, is excited to announce the appointment…

Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

4 months ago

- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose…

Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria

4 months ago

  Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous…

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

5 months ago

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first…

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

5 months ago

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S.  SIMLANDI is the first…

Foothold Technology and NY Health Home Coalition Respond to the Impact Budget Cuts Will Have for Vulnerable New Yorkers

5 months ago

NEW YORK--(BUSINESS WIRE)--In response to the recent executive budget decision by Governor Kathy Hochul, which includes a substantial $125 million…

CGFNS International Unveils New Think Tank to Advance Health Workforce Development Scholarship and Solutions Worldwide 

5 months ago

PHILADELPHIA, PA / ACCESSWIRE / February 23, 2024 / CGFNS International announced today it has established a Global Health Workforce…